Cell Therapy Technologies Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Cell Therapy Technologies Market Size

The global cell therapy technologies market generated notable revenue in 2024 and is expected to grow at a decent CAGR during 2025-2034, due to the rising prevalence of chronic diseases, cancer, and genetic disorders, which can be treated using innovative cell-based treatments. As per WHO, in 2022, around 20 million new cancer diagnoses occurred, along with 9.7 million cancer-related deaths. The market growth is also driven by advancements in cellular therapies for a wide range of chronic diseases, particularly in the field of immunotherapy and regenerative medicine. Cell therapies, which involve the use of living cells to treat various conditions, offer promising solutions for treating them. The market’s expansion is attributed to increased research in cell-based therapies, evolving healthcare needs, and the increasing prevalence of diseases that can benefit from these treatments.
 

Moreover, the demand for cell-based therapies is increasing due to advancements in manufacturing technologies, which make cell therapies more accessible and affordable. However, the market faces challenges related to the high cost of cell-based therapies and the complexity of manufacturing these therapies.
 

Cell Therapy Technologies Market Trends

The cell therapy technologies industry is undergoing significant changes, with several trends shaping its future growth. One of the key trends is the increasing adoption of personalized cell therapies. This approach tailors treatments to individual patients’ genetic profiles, offering more effective and targeted therapeutic options. Personalized treatments are particularly prominent in the field of oncology, where cellular therapies like CAR-T cell therapy are showing promise in targeting specific cancer cells.
 

Moreover, the development of allogeneic cell therapies, where cells are derived from healthy donors, is gaining traction as it offers the potential for off-the-shelf treatments. This contrasts with autologous therapies, which involve using a patient’s own cells. Allogeneic therapies are expected to be more cost-effective and widely accessible, which could expand their application in clinical settings. Another trend influencing the market is the continued investment in automation and artificial intelligence (AI) to streamline cell therapy manufacturing. These technologies aim to address the complexities and cost barriers associated with large-scale production of cell therapies.
 

Cell Therapy Technologies Market Analysis

The T-cell segment in the cell therapy technologies market is expected to witness significant through 2034 due to the increasing number of approved therapies in oncology and immunotherapy. T-cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, have revolutionized cancer treatment. CAR-T therapy has shown substantial efficacy in treating various types of blood cancers, including leukemia and lymphoma. These therapies are designed to genetically modify a patient's T-cells to better recognize and attack cancer cells.
 

As of 2023, several CAR-T therapies have gained approval from regulatory bodies like the U.S. Food and Drug Administration (FDA), including Kymriah, Yescarta, and Tecartus, among others. This success has spurred ongoing research into expanding T-cell therapies for solid tumors, autoimmune diseases, and other conditions. The growing body of evidence supporting the effectiveness of T-cell-based therapies, combined with increasing cancer incidences globally, is set to drive demand for these technologies. However, challenges such as the high cost and the potential for severe side effects limit the broader adoption of these therapies.
 

Based on end use, the Cell banks and research institutes segment in the cell therapy technologies market is expected to hold the largest share by 2034. These organizations provide the necessary infrastructure and expertise for the development, storage, and distribution of cell-based therapies. Cell banks are responsible for the production and maintenance of high-quality cell lines, which are essential for research, clinical trials, and the commercial production of cell therapies. Research institutes, on the other hand, help in advancing scientific knowledge in cell biology and developing new therapeutic applications for cell therapies. These institutions work closely with biotech and pharmaceutical companies to drive innovation in cellular medicine, including stem cell research, tissue engineering, and gene editing technologies like CRISPR. The increasing investments in research activities, both public and private, are expected to further fuel the market. Collaboration between pharmaceutical companies, research institutes, and healthcare providers will likely accelerate the development of new and more effective cell therapies, providing growth opportunities in the coming years.
 

North America cell therapy technologies market is expected to maintain its CAGR growth through 2034. The region’s dominance is driven by several factors, including a well-established healthcare infrastructure, advanced research & development capabilities, and a high prevalence of diseases that are treatable with cell therapies. The United States is the largest market for cell therapies, due to its robust pharmaceutical industry and regulatory support for the commercialization of novel therapies. The approval of CAR-T therapies, as well as the growing number of clinical trials and FDA-approved cell therapies, has positioned North America at the forefront of innovation in cell therapy technologies. Moreover, the region benefits from a strong pipeline of cell-based therapies, backed by substantial funding and investment in biotech companies, which are key drivers of market growth. The U.S. government’s initiatives to support regenerative medicine and immunotherapy research, along with favorable reimbursement policies, have further contributed to North America's dominant position in the market.
 

Cell Therapy Technologies Market Share

The cell therapy technologies market is highly competitive, with several key players driving innovation in this field. Leading companies in this market include:

• Becton Dickinson and Company
• Avantor Inc.
• Corning Incorporated
• GE Healthcare
• FUJIFILM Irvine Scientific, Inc.
• Sartorius AG
• Danaher Corporation
• Thermo Fisher Scientific, Inc.
• Lonza Group AG
• Bio-Techne Corporation
• Merck KGaA
• Terumo BCT
   

Companies such as Novartis, Gilead Sciences, Bristol Myers Squibb, and Merck & Co., also have made significant investments in the development of CAR-T and other cell-based therapies. These companies are actively involved in expanding their cell therapy portfolios, improving manufacturing processes, and exploring new therapeutic indications.
 

In addition, emerging biotech companies like Kite Pharma, Autolus Therapeutics, and Celyad Oncology are working on cutting-edge technologies that aim to improve the efficacy and safety profiles of cell therapies. The cell therapy technologies market is also witnessing strategic partnerships and collaborations between pharmaceutical companies, academic institutions, and research organizations, which are aimed at accelerating the development and commercialization of cell therapies.
 

Cell Therapy Technologies Industry News

• In January 2024, Novartis successfully completed a Phase III trial for its novel T-cell therapy targeting solid tumors. This groundbreaking achievement could potentially expand the use of T-cell therapies beyond blood cancers and into more complex conditions like breast and lung cancer. Additionally, Gilead Sciences is advancing the development of its new off-the-shelf cell therapy product, aimed at addressing the challenges of autologous cell therapies. If successful, this product could provide a cost-effective and scalable solution for treating a wide range of cancers, making it a potential game-changer in the market.
   
• In February 2025, Bluebird Bio announced the successful completion of a Phase II trial for its gene-edited T-cell therapy aimed at treating sickle cell disease. The therapy, which utilizes CRISPR-based gene editing, demonstrated significant improvements in hemoglobin levels and reduced the frequency of painful episodes in patients. Bluebird Bio plans to submit the data to regulatory agencies for approval in 2025, marking a major milestone in advancing gene therapies for genetic disorders. The company also aims to expand its research efforts to apply the therapy to other genetic conditions, further strengthening its position in the growing cell therapy technologies market.